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http://dx.doi.org/10.1016/j.ccell.2015.08.001SUMMARYERK signaling requires RAS-induced RAF dimerization and is limited by feedback. Activated BRAF mutants
evade feedback inhibition of RAS by either of twomechanisms. BRAF V600mutants are activatedmonomers
when RAS activity is low; all other activating BRAF mutants function as constitutive RAS-independent di-
mers. RAF inhibitors effectively inhibit mutantmonomers, but not dimers; their binding to one site in the dimer
significantly reduces their affinity for the second. Tumors with non-V600E BRAF mutants are insensitive to
these drugs, and increased expression of BRAF V600E dimers causes acquired resistance. A compound
that equally inhibits both sites ofmutant RAF dimers inhibits tumors driven by either class ofmutants or those
BRAF V600E tumors with dimer-dependent acquired resistance to monomer-specific inhibitors.INTRODUCTION
The oncogenic activation of ERK signaling output is character-
istic of many cancers. Physiologic activation of the pathway
occurs when upstream signals stimulate the binding of RAS to
guanosine triphosphate (GTP) (Luo et al., 1996; Rajakulendran
et al., 2009). Activated RAS binds to RAF family members and
causes their homo- and heterodimerization and activation
(Freeman et al., 2013). This in turn initiates the MEK/ERK kinase
cascade and phosphorylation of effectors of the pathway by
ERK. Activation of ERK also causes an array of negative regula-
tory events that serve to inhibit the pathway. ERKphosphorylates
and inhibits receptors (AvrahamandYarden, 2011), theRASgua-
nosine diphosphate-GTP exchange factor SOS (Dong et al.,Significance
We show that a fundamental property of activating BRAFmuta
occurs determines their sensitivity to current RAF inhibitors.
monomers (BRAF V600) but not dimers. These findings can
and guide their treatment. A compound that is unaffected by
by activated mutant BRAF dimers or monomers and at doses
Such drugs may be useful in treating any tumor driven by an ac
monomer’’ inhibitors, which are limited by dimer-driven acqui
370 Cancer Cell 28, 370–383, September 14, 2015 ª2015 Elsevier In1996), and wild-type (WT) CRAF and BRAF (Dougherty et al.,
2005). It also increases the expression ofmembers of theSprouty
and DUSP families of proteins that inhibit the pathway (Pratilas
et al., 2009). The former inhibit RTK activation of RAS, whereas
the latter areMAPKphosphatases (Langet al., 2006). Thus, nega-
tive feedback limits the amplitude and duration of the ERK signal.
Oncogenic mutations of NRAS, KRAS, BRAF, MEK1, and NF1
drive the ERK-dependent growth ofmany human cancers. These
mutations activate both downstream signaling and potent nega-
tive feedback, as evidenced by reactivation of upstream and par-
allel components of the pathway in cells exposed to MEK or RAF
inhibitors (Corcoran et al., 2012; Lito et al., 2012;Montero-Conde
et al., 2013). We hypothesize that the elevated signaling output
necessary for transformation requires selection of oncoproteinsnts is their RAS independence. Themechanism whereby this
These drugs potently inhibit signaling driven by active RAF
be used to characterize BRAF mutants detected in tumors
induction of negative cooperativity inhibits signaling driven
lower than those required to inhibit wild-type RAF signaling.
tivating BRAF mutation and could supplant current ‘‘BRAF-
red resistance.
c.
Figure 1. Activating BRAFMutants Signal in
a RAS-Independent Manner
(A) NIH 3T3 cells stably transduced with retrovirus
carrying doxycycline-inducible WT BRAF or the
indicated mutants were treated with doxycycline
(30 ng/ml) for 24 hr. Expression and/or phosphor-
ylation of the indicated proteins was assayed
by western blot. Cellular RAS-GTP levels were
determined using the active RAS pull-down assay.
(B) SKBR3 cells transiently expressing V5-tagged
WT BRAF or the indicated mutants were treated
with lapatinib (1 mM) or DMSO for 1 hr. Cell lysate
from each sample was divided into two portions
for immunoprecipitation with either anti-V5 anti-
body or anti-CRAF antibody, followed by an in vitro
kinase assay with 0.5 mg K97R MEK1 protein. Five
percent of the whole-cell extracts were used for
immunoblot (input panels). l.e., longer exposure,
s.e., short exposure.
(C) Ectopic expression of V5-tagged WT BRAF or
the indicated mutants were expressed in SKBR3
cells followed by lapatinib treatment (1 mM for 1 hr).
ERK signaling was assessed by western blot, as
in (A).
See also Figure S1.with decreased sensitivity to negative feedback. Mutations and
translocations of RAF family genes are common in human tumors
(Wan et al., 2004; Davies et al., 2002; Palanisamy et al., 2010).
V600E is the most common BRAFmutation, but non-V600E mu-
tations account for more than 50% of the RAF mutations in lung
cancers (Paik et al., 2011) and occur in many other tumors. The
kinase activity of many of these mutants has been shown to be
activated compared with WT, but some BRAF mutations are ki-
nase dead or have lower activity than WT BRAF (Wan et al.,
2004). RAF fusions and truncations inwhichpart of theamino-ter-
minal domain of RAF is usually deleted also occur rarely in many
tumors and in a high percentage of pilocytic astrocytomas
(Berghoff and Preusser, 2014). Here, we ask how activating
mutations of RAF hyperactivate signaling in the setting of ERK-
dependent feedback inhibition of RAS.
RESULTS
Activating Mutants of BRAF Hyperactivate ERK
Signaling and Suppress RAS Activation
RAS-GTP is suppressed in BRAF V600E tumor cells by ERK-
dependent feedback (Lito et al., 2012). We asked whether thisCancer Cell 28, 370–383, Seis a general property of tumor cells with
activated mutant BRAFs. Levels of RAS-
GTP and CRAF phosphorylation at serine
338 (pCRAF S338, amarker of CRAF acti-
vation) (Mason et al., 1999) were much
lower in tumor cells with activating
BRAF V600E, K601N, L597V, L597R, or
G469A mutations than in those with WT
RAF (Figure S1A). In contrast, levels of
phosphorylated MEK (p-MEK) are highly
elevated in RAF mutant cells even
compared to those with mutant RAS.These results suggest that MEK is activated but RAS and
CRAF are feedback inhibited in tumor cells with activating
BRAF mutants.
To determine whether suppression of RAS activity is a gen-
eral property of these mutants, we expressed mutant BRAFs
in an inducible fashion in NIH 3T3 cells (Figure 1A). Induction
of the expression of BRAF V600E, V600K, K601E, L597Q,
G469A, G469V, or G464V to levels comparable to those of
endogenous BRAF caused significant induction of p-MEK
and p-ERK and marked inhibition of RAS-GTP and pCRAF
S338. Induction of WT BRAF caused minor increases in
p-MEK and p-ERK and had no effect on RAS-GTP or pCRAF
S338. Thus, activated BRAF mutants significantly increase
ERK signaling despite causing feedback inhibition of RAS ac-
tivity to almost undetectable levels. By contrast, kinase-dead
BRAF D594G and low-activity BRAF G466E and D287H
marginally activated ERK signaling and didn’t inhibit RAS
function. These mutants may function in a fundamentally
different way than the activating mutants, as previously sug-
gested (Heidorn et al., 2010). In this paper, we focus on acti-
vating mutants of BRAF and how they function in cells in which
RAS is feedback inhibited.ptember 14, 2015 ª2015 Elsevier Inc. 371
















WT N Y Y N Y Y
V600E Y N N Y Y Y
V600K Y N N Y Y Y
V600D Y N N Y Y Y
V600R Y N N Y Y Y
V600M Y N N Y Y Y
K601E Y N Y N Y N
K601N Y N Y N Y N
K601T Y N Y N Y N
L597Q Y N Y N Y N
L597V Y N Y N Y N
G469A Y N Y N Y N
G469V Y N Y N Y N
G469R Y N Y N Y N
G464V Y N Y N Y N
G464E Y N Y N Y N
KIAA1549-BRAF Y N Y N Y N
p61 WT Y N Y N Y N
p61 V600E Y N N N Y NActivation of Signaling by Hyperactivated RAF Mutants
Is RAS Independent
Our findings imply that activated BRAF mutants signal in a RAS-
independent manner and are thus insensitive to upstream feed-
back. To test this hypothesis, we used the ERBB2 amplified
breast cancer cell SKBR3 inwhichRASactivity andERKsignaling
are potently suppressed after 1 hr exposure to the HER2 inhibitor
lapatinib (Figure S1B). This system allows us to assess the RAS
dependence of exogenously expressed RAF mutants. Lapatinib
inhibited ERK signaling in SKBR3 cells overexpressing WT
BRAF but failed to do so in those that express activating BRAF
mutants (Figures 1B and S1C). Moreover, when CRAF or BRAF
were immunoprecipitated from these cells, BRAF-associated ki-
nase activity was sensitive to lapatinib only in cells expressing
WT BRAF, not in those expressing mutant BRAF (Figures 1B
and S1C). In contrast, CRAF-associated kinase activity was sen-
sitive to lapatinib in all cells. Thus, the kinase activity of activating
BRAFmutants isRAS independent. Toexclude thepossibility that
their activity requires low levels of residual RAS-GTP, the R188L
mutation that disrupts the RAS-BRAF interaction (Fabian et al.,
1994) was introduced into the activating BRAF mutants and did
not affect their ability to drive signaling (Figure 1C). To further
confirm that these activating BRAFmutants signal in a RAS-inde-
pendentmanner,weusedconditionalRAS-lessmouseembryofi-
broblasts (MEFs) (Drosten et al., 2014). Knockout (KO) ofKras, the
only RAS gene in these cells, causes their proliferative arrest and
abrogates ERK signaling, but they remain viable. All of the acti-
vating BRAF mutants rescue MEK/ERK phosphorylation in these
cells, butWTBRAFdoesnot (FigureS1D).Wehave tested16acti-
vating BRAF mutants (Table 1), and all signal in a RAS-indepen-
dent manner.372 Cancer Cell 28, 370–383, September 14, 2015 ª2015 Elsevier InRAS-Independent BRAF Mutants Fall into Two Classes:
Active Constitutive Dimers and Mutants that Are Active
as Monomers in Cells with Low RAS Activity
Previous data suggested that V600E BRAF can signal as a
monomer and is thus RAS independent (Poulikakos et al.,
2011). We asked whether this is the general mechanism that un-
derlies the RAS independence of activating RAF mutants. To
address this question, we used the R509H and R401H/A muta-
tions that impair dimerization of BRAF and CRAF, respectively,
and eliminate their kinase activity (Poulikakos et al., 2010).
R509H or R401H were introduced into BRAF or CRAF and mul-
tiple BRAF and CRAF mutants or truncations and expressed in
SKBR3 cells (Figure 2A). ERK signaling in SKBR3 cells express-
ing these mutants was assessed after lapatinib treatment (low
RAS-GTP state). ERK signaling was undetectable in cells when
WT BRAF was overexpressed. Low levels of p-ERK were de-
tected in cells overexpressing CRAF, but not in cells with
CRAF 401H. The effects of R509H on ERK signaling were tested
in 15 different activated BRAFmutants that were identified in hu-
man tumors (Figure 2A; Table 1). ERK signaling driven by 11 of
the 15 was reduced to very low levels. The 4 mutants unaffected
by the R509H were all V600 mutants (V600E/K/D/R). In contrast,
the activities of K601 mutants, including K601E, are abrogated
by the R509H mutation.
The results suggest that in cells with low RAS activity, BRAF
V600 mutants signal as active monomers, whereas all other
BRAF-activating mutants signal as constitutive, RAS-indepen-
dent dimers. We confirmed this conclusion in the RAS-deficient
MEFs. BRAF V600 R509H mutants restore ERK signaling in
these cells, but R509H mutants of non-V600 BRAF mutants do
not (Figure S2A).c.
Figure 2. Activated RAF Proteins that Signal
as Dimers Are Resistant to Vemurafenib
(A) SKBR3 cells were transfected with the indi-
cated plasmids. After 24 hr, the cells were treated
with 1 mM lapatinib for 1 hr. Cell lysates were then
analyzed by western blot.
(B) SKBR3 cells transiently co-expressing Flag-
tagged and V5-tagged WT or mutant BRAF pro-
teins were treated with lapatinib (1 mM for 1 hr).
BRAF dimerization was determined by immuno-
precipitation.
(C) SKBR3 cells were transfected with the
indicated plasmids. After 24 hr, the cells were
treated with 1 mM lapatinib for 1 hr, followed
by 1 mM vemurafenib for 1 hr. The indicated
endogenous or ectopic proteins were assayed by
western blot.
See also Figure S2.We asked whether the non-V600 BRAF-activating mutants
function as BRAF homodimers or BRAF/CRAF heterodimers.
When these mutants were expressed in Raf1, which encodes
CRAF, KO MEFs, they all potently activate ERK signaling and
remain sensitive to R509H (Figure S2B). Thus, CRAF is not
required for activation of ERK signaling by BRAF mutants that
signal as constitutively active dimers. We evaluated the ability
of these BRAF mutants to homodimerize and to heterodimerize
with CRAF as a function of cellular RAS activity. We co-ex-
pressed V5- and FLAG-tagged BRAF mutants in SKBR3 cells
and assessed co-precipitation of V5 with either FLAG (mutant
BRAF homodimers) or CRAF (mutant BRAF/WT CRAF hetero-
dimers) (Figure 2B). In control cells with adequate RAS-GTP
levels, either WT BRAF or BRAF mutants form both BRAF ho-
modimers and BRAF/CRAF heterodimers. One hour after inhibi-Cancer Cell 28, 370–383, Setion of RAS activity with lapatinib, BRAF/
CRAF heterodimers were lost from all
cells. BRAF homodimers were lost in
cells overexpressing WT BRAF or BRAF
V600 mutant alleles, but ERK phosphory-
lation was abrogated only in the former
(Figure 2B). Thus, the formation of
BRAF V600E/K homodimers is RAS
dependent, but both BRAF V600E/K di-
mers and monomers can activate ERK
signaling. In contrast, dimerization and
activity of non-V600 BRAF mutants are
RAS independent (Figure 2B; Table 1).
We conclude that activating BRAF
mutants evade feedback by either of
two mechanisms: the dimerization of
V600 mutants remains RAS dependent,
but their activity is not dependent on
dimerization. Monomers of all non-V600
BRAF-activating mutants are inactive,
and they all signal as active RAS-inde-
pendent homodimers.
In cancer, RAF kinase is also acti-
vated by a variety of translocations and
aberrant splice forms that encode fusionor truncated proteins in which an N-terminal domain contain-
ing the RAS-binding site is almost always deleted (Figure S2C).
Engineered deletion of this domain has been shown to result in
constitutive dimerization and activation (Cutler et al., 1998), so
it seems likely that these fusions are also activated in this way.
Cat C, an engineered N-terminal deletion of CRAF, and p61
WT BRAF, an engineered N-terminal deletion of BRAF, are
activated constitutive dimers whose activity is abrogated by
the R401H and R509H mutants respectively (Figure 2A). Simi-
larly, ESRP1-CRAF and KIAA1549-BRAF are tumor-derived
fusion proteins in which the N-terminal domain of CRAF or
BRAF has been replaced by the fusion partner (Figure S2C).
They also activate ERK signaling in a RAS-independent
manner, and their activity is abrogated by the R401A and
R509H mutations, respectively (Figure S2D). Thus, fusionsptember 14, 2015 ª2015 Elsevier Inc. 373
Figure 3. Expression of BRAF V600E Dimers
Causes Resistance to Vemurafenib
(A) A375 cells expressing inducible GFP, V5-tag-
ged BRAF V600E, or FLAG-tagged NRAS Q61K
were treated with the indicated concentrations of
doxycycline for 24 hr, followed by treatment with
vemurafenib (1 mM for 1 hr).
(B and C). A375 cells expressing inducible GFP,
V5-tagged BRAF V600E, or V5-tagged BRAF
V600E R509H were treated with either 0.02 mg/ml
(B) or 0.2 mg/ml (C) doxycycline for 24 hr. Cells
were then treated with vemurafenib at the indi-
cated doses for 1 hr. Expression of the indicated
proteins was assessed by western blot.
See also Figure S3.and truncated RAFs that lack the N-terminal domain are
RAS-independent kinases whose activity is dependent on their
constitutive dimerization. A truncated p61 BRAF V600E was
found to be responsible for the acquired resistance of some
melanomas to RAF inhibitors (Poulikakos et al., 2011). This
truncated BRAF V600E is a RAS-independent dimer, but its
activity is not abrogated by R509H (Figure 2A). The N-terminal
truncation of BRAF V600E causes it to dimerize in a RAS-inde-
pendent manner, but the V600E mutation causes it to be active
as a monomer or dimer. Thus, with the singular exception
of BRAF mutants with V600 missense mutations, so far all
tested activating mutations, translocations, and fusions
of RAF bypass ERK-dependent feedback by constitutively di-
merizing in a RAS-independent manner. Uniquely, the V600
mutants do so by functioning as active monomers when
RAS-GTP is low.
RAF Mutants that Act as Constitutive Dimers Are
Resistant to RAF Inhibitors
The RAF inhibitor vemurafenib inhibits ERK signaling in tumors
in which it is driven by BRAF V600E and not in those in which it374 Cancer Cell 28, 370–383, September 14, 2015 ª2015 Elsevier Inc.is driven by RAS (Poulikakos et al.,
2010). We used the SKBR3, low RAS-
GTP (lapatinib-treated) system to deter-
mine the sensitivity to vemurafenib of
activating RAF mutants that signal as
constitutive dimers. All such mutants
were resistant, including non-V600
BRAF mutants, the truncated CRAF
(Cat C), and BRAF (p61 WT) proteins
(Figure 2C; Table 1) and the two tested
fusion proteins (Figure S2D). Vemurafe-
nib transactivates truncated WT dimers,
whereas activated BRAF mutants that
constitutively dimerize are resistant to
the drug but not activated further (Fig-
ure 2C). The only BRAF mutants that
are sensitive to this drug are the four
V600 mutants we tested (Figure 2C;
Table 1). Similar results were observed
in Raf1 KO MEFs (Figure S2E). So far
there is an absolute correlation betweenthe ability of a mutant to signal as a monomer and its sensitivity
to vemurafenib.
Expression of BRAF V600E Dimers Causes Acquired
Resistance to Vemurafenib
These results suggest that increased expression of activated
RAF dimers will cause resistance to RAF inhibitors. Expression
of p61 BRAF V600E ormutant NRAS andBRAF V600E amplifica-
tion are common causes of acquired resistance to these drugs
(Nazarian et al., 2010; Poulikakos et al., 2011; Shi et al., 2012).
p61 BRAF V600E-dependent acquired resistance depends on
its dimerization (Poulikakos et al., 2011), and mutant NRAS pro-
motes the dimerization of BRAF V600E with CRAF (Figure S3A).
However, the mechanism whereby BRAF V600E amplification
induces resistance remains unclear. We used A375, a melanoma
cell line homozygous for BRAF V600E, to generate stable
clones that expressed Tet-regulated BRAF V600E, BRAF
V600E R509H, or NRAS Q61K. Increased expression of either
BRAF V600E, which is used to modelBRAF V600E amplification,
or mutant NRAS caused increasing resistance to inhibition of
ERK signaling by vemurafenib (Figure 3A). Expression of mutant
NRAS was associated with an elevation of cellular RAS-GTP
levels (data not shown) and induction of BRAF V600E-CRAF het-
erodimers (Figure S3A). It is likely that induction of these RAS-
driven dimers is responsible for drug resistance.
By contrast, in cells in which BRAF V600Ewas overexpressed,
significant BRAF V600E homodimerization occurs. Increasing
amounts of plasmids encoding FLAG-tagged BRAF V600E
were transfected into A375 cells that expressed V5-tagged
BRAF V600E. As shown in Figure S3B, homodimers were de-
tected when either tag was immunoprecipitated. Homodimer
levels increased in direct proportion to the levels of expression
of FLAG-tagged BRAF V600E. Under these conditions, neither
V600E BRAF/CRAF heterodimerization nor induction of RAS-
GTP occurs. These results suggest that BRAF V600E amplifica-
tion causes acquired resistance to RAF inhibitors because it
increases BRAF V600E homodimerization. To test this idea, we
compared the effects of overexpressing BRAF V600E with those
induced by overexpressing the dimerization impaired BRAF
V600E R509H. As shown in Figure 3B, cells expressing modest
levels of BRAF V600E or BRAF V600E R509H are similarly sensi-
tive to vemurafenib (half-maximal inhibitory concentration [IC50]
 100–300 nM). However, at higher levels of expression (Fig-
ure 3C), cells with BRAF V600E were significantly less sensitive
than those expressing the R509H mutant (IC50 > 10,000 versus
300 nM). Thus, these data suggest thatBRAF V600E amplifica-
tion causes acquired resistance by increasing levels of BRAF
V600E homodimers.
Binding of RAF Inhibitors to One Site in the Dimer
Reduces Their Affinity for the Other
Binding of inhibitors to CRAF or BRAF induces both RAF dimer-
ization and the allosteric transactivation of the unbound proto-
mer of the dimer (Hatzivassiliou et al., 2010; Poulikakos et al.,
2010). However, neither mechanism explains why ATP-compet-
itive inhibitors do not bind to both sites and inhibit the dimer.
Allosteric regulation of multimeric protein complexes is often
associated with cooperative effects on ligand binding. We took
advantage of the availability of systems in which the ability of
drug to inhibit active monomeric or dimeric mutant BRAF can
be compared to assess the possibility that drug binding to
one protomer of the dimer reduces its affinity for the other. p61
BRAF V600E signals as a constitutive dimer, whereas p61
BRAF V600E R509H signals as a monomer (Poulikakos et al.,
2011). p61 BRAF V600E and p61 BRAF V600E R509H were
each expressed in SKBR3, and the effects of RAF inhibitors on
ERK signaling were assessed in these cells under low-RAS
conditions. Vemurafenib inhibits ERK signaling in SKBR3 cells
expressing p61 BRAF V600E R509H or BRAF V600E at similar
concentrations (IC50 100–300 nM) (Figure S4A). We take this
as the concentration required to inhibit the monomer. Binding
of drug to one protomer of truncatedWT dimers causes transac-
tivation of the other. We find that the 50% induction of p61 WT
BRAF-driven ERK signaling by vemurafenib also occurs at
approximately 100–300 nM (Figures S4B and S4C). This is thus
the concentration required to bind to monomers and to the first
site of the dimer.
By contrast, more than 30-fold higher concentrations of ve-
murafenib were required to inhibit ERK driven by p61 V600E di-
mers than by p61 V600E R509Hmonomers (Figure 4A) The sameCanrelative difference was observed with another, more potent,
RAF inhibitor, dabrafenib (Figure 4A). We take the concentration
required to inhibit ERK signaling in the p61 BRAF V600E cells as
the concentration required inhibiting both sites in the dimer.
These data therefore imply that the relative affinity of vemurafe-
nib for the first binding site in a BRAF homodimer is 30-fold
higher than that for the second site when the first site is occupied
by drug. In isogenic p61 BRAF experiments, the RAF mutants
were expressed in a heterologous cellular system: SKBR3. To
interrogate a tumor system in which activated BRAF V600E
mutant monomers or dimers are expressed, we used SK-
MEL239, a BRAF V600E melanoma cell line, and SK-MEL239
C4, a vemurafenib-resistant clone of SK-MEL239 (Poulikakos
et al., 2011) that expresses p61 V600E dimers (Figure S4D).
Thirty-fold higher concentrations of dabrafenib were required
to inhibit ERK signaling in the latter compared with the former
(Figure 4B). The data suggests that binding of the drug to the first
site in the dimer reduces its affinity for the second and that this
explains why monomer-driven ERK signaling is so much more
sensitive to these drugs than that driven by dimers.
Identification of a Compound that Inhibits RAF
Monomers and Dimers at Similar Concentrations
To identify compounds that inhibit monomers and dimers with
similar potency, we screened 22 known RAF inhibitors against
SK-MEL-239 and SK-MEL-239 C4. Results for six of these com-
pounds are shown in Figure S4D, and their chemical structures
are shown in Table S1. The concentrations required for five of
these six to inhibit ERK signaling driven by the dimer were
significantly higher (5- to 85-fold) than those that inhibit mono-
mer-driven signaling (Figures 4B and S4D). LGX818 inhibited
monomer-driven signaling at 14 nM, and dimer signaling at
287 nM, despite its high potency and low off-rate (see the
following discussion). In contrast, BGB659, a type II, ATP-
competitive RAF inhibitor (compound 27 from Gould et al.,
2011), inhibited ERK signaling driven by p61 BRAF V600E dimers
and BRAF V600E monomers at similar doses (Figures 4B and
S4D). Its inhibition of ERK signaling is mediated by its binding
to BRAF; the T529 BRAF gatekeeper mutation (Heidorn et al.,
2010) confers resistance to the drug (Figure S4E). In cells that ex-
press either BRAF V600E T529N or p61 BRAF V600E T529N,
ERK signaling is resistant to both vemurafenib and BGB659
but not to the MEK inhibitor trametinib.
BGB659 could inhibit BRAF V600E dimers by a variety of
mechanisms. We show later (Figure 6B) that, like most RAF in-
hibitors, BGB659 induces RAF dimerization, so it is not a ‘‘dimer
breaker.’’ We have not been able to recreate the resistance of
RAF dimers to inhibitors in defined in vitro systems.We therefore
developed a cellular system in which only one site of the RAF
dimer is occupied by a RAF inhibitor and used it to determine
the concentration of drug required to bind to and inhibit the
second site when the first is already bound. The RAF inhibitor
LGX818, which has a very slow off-rate, was used. After 1 hr
exposure of BRAF V600E tumor cells to vemurafenib or
LGX818, ERK signaling is inhibited (Figure S4F). One hour after
washout of the drug, ERK phosphorylation returned to pre-expo-
sure levels in the vemurafenib-treated cell, but remains inhibited
in the LGX818-treated cells. Thus, after 1 hr of washout, the
BRAF V600E monomer remains bound to LGX818.cer Cell 28, 370–383, September 14, 2015 ª2015 Elsevier Inc. 375
Figure 4. Identification of an Equipotent
Inhibiter of Mutant BRAF Monomers and
Dimers
(A) SKBR3 cells expressing p61 V600E or p61
V600E R509H were treated with increasing con-
centrations of vemurafenib or dabrafenib for 1 hr.
Expression of phosphorylated MEK and phos-
phorylated ERK were assessed by western blot.
(B) IC50 values of p-ERK inhibition for a panel of
compounds in SK-MEL-239 parental cells (BRAF
V600E) or the C4 clone (which expresses p61
BRAF V600E) were calculated on the basis of
densitometry analysis of western blot results
(n = 3), as shown in Figure S4D. Mean values are
listed in the table.
(C) A375 and SK-MEL-30 cells were treated with
DMSO or 3 mM LGX818 for 1 hr. Cells were then
washed three times with PBS and then placed in
drug-free media for the indicated times. p-ERK
was assessed by western blot (top) and quanti-
tated by densitometry to generate the dose-
response curves using Prism6 (bottom); p-ERK
levels relative to those from DMSO-treated cells
as a function of time post-treatment are shown in
the accompanying graph.
(D) A375, SK-MEL-239 C4, and SK-MEL-30
cells were treated with 1 mM LGX818 for 1 hr,
followed by drug washout and treatment with the
indicated compounds for an additional 1 hr. The
indicated fold changes of p-ERK IC50 values were
calculated on the basis of the curves, as shown in
Figure S4Hd.
See also Figure S4 and Table S1.SK-MEL-30 is a cell line with mutant NRAS and WT RAF. As
expected, vemurafenib activates ERK signaling in these cells
by binding to one protomer of WT RAF dimers and transactivat-
ing the other (Figure S4G). One hour after washout of vemurafe-
nib, p-ERK returned to baseline, likely because of dissociation of
drug from the first site. LGX818 also induced p-ERK at low con-
centrations, but, in contrast to vemurafenib, induction persisted
after 1 hr of washout of the drug, consistent with persistent bind-
ing to the first site because of its low off-rate (Figure S4G). Peak
induction of ERK occurred at 100 nM LGX818 and actually
increased 1 hr after the drug was washed out. At higher concen-
trations (300–3,000 nM), LGX818 caused a concentration-
dependent inhibition of ERK signaling. This is consistent with
its binding to and inhibiting both sites in the dimer. At these
concentrations, washout for 1 hr hyperactivates ERK signaling
compared with untreated controls. This result suggests that376 Cancer Cell 28, 370–383, September 14, 2015 ª2015 Elsevier Inc.the dissociation of drug from the second
site is more rapid than that from the
first site. The hyperactivation after drug
washout is consistent with dissociation
of drug from the second site, resulting
in accumulation of the half-bound, trans-
activated RAF dimer.
This was confirmed when A375 (BRAF
V600E) and SK-MEL-30 (NRAS Q61K)
cells were treated with 3 mM LGX818 for
1 hr, followed by washout of drug andincubation in normal media (Figure 4C). p-ERK was potently in-
hibited in both cell lines. After washout, p-ERK remained in-
hibited in A375 for up to 24 hr, with a slight increase at that
time, consistent with the very slow off-rate from the BRAF
V600E monomer. After drug was withdrawn from SK-MEL-30,
which contains WT RAF dimers, p-ERK rose rapidly, reaching
a maximum approximately 1 hr after washout, with a half-time
of 10 min. This is consistent with a rapid off-rate of drug bound
to the second site in the dimer. In these cells, the maximum
p-ERK was about five times higher than basal. After reaching
this peak, p-ERK fell slowly, consistent with the slow off-rate of
this drug from the first site in the dimer, and was still 3-fold
elevated compared with basal 24 hr after washout (Figure 4C).
Thus, after exposure of cells to high concentrations of
LGX818, washout of the drug for 1 hr leads to accumulation
of activated half-bound dimers. We reasoned that the
Figure 5. BGB659 Effectively Inhibits
Vemurafenib-Resistant ERK Signaling
(A and B) A375 cells expressing inducible GFP
(control), BRAF V600E, or NRAS Q61K were
treated with doxycycline (2 mg/ml for 24 hr), fol-
lowed by treatment with vemurafenib (A) or
BGB659 (B) at the indicated concentrations. Cell
lysates were then analyzed by western blot using
the antibodies indicated.
(C) SKBR3 cells were transfected with plasmids
encoding the indicated WT or mutant proteins.
After 24 hr, cells were treated with BGB659 (1 mM
for 1 hr). Expression and/or phosphorylation of the
indicated proteins was assayed by western blot.
See also Figure S5.concentration of other RAF inhibitors that is required to inhibit
ERK signaling in these cells 1 hr after LGX818 washout reflects
the relative affinity of the drug for the second (unoccupied) site.
We used this system to determine the concentrations of six
RAF inhibitors that are required to bind the second site of the
dimer when the first is occupied by drug. For each inhibitor,
this value was compared with the concentration at which it in-
hibits BRAF V600E monomers. Five of the six compounds in-
hibited ERK phosphorylation in A375 BRAF V600E melanoma
cells at concentrations ranging from 10–100 nM (Figure S4H-
a). This is the concentration required to inhibit the monomer (or
the first site in the dimer). To determine the concentration of
these drugs required inhibit the second site when the first is
bound to drug, SK-MEL-30 NRAS mutant cells were exposed
to 1 mM LGX818 for 1 hr, after which it was washed out for
1 hr. Other RAF inhibitors were then added for 1 hr to assess
the concentration at which they inhibit ERK phosphorylation.
All the drugs were able to inhibit p-ERK but, for five of the six,
at concentrations much greater than those at which they inhibit
the monomer (0.3–10 mM) (Figure S4H-b versus Figure S4H-a).Cancer Cell 28, 370–383, SeOnly BGB659 inhibited the monomer
and the second site of the WT RAF dimer
at approximately the same concentra-
tions. Very similar results were obtained
when the same experiment was done in
SK-MEL-239 C4 with BRAF V600E di-
mers (p61 BRAF V600E) (Figure S4H-c).
These results are shown graphically (Fig-
ure S4H-d) and as ratios of concentra-
tions required to inhibit the second site
compared with those that inhibit the
monomer (Figure 4D).
These data suggest that binding of
most RAF inhibitors to one site in WT or
mutant RAF dimers substantially reduces
their affinity for the second site and that
this accounts for the resistance of
dimer-driven ERK signaling to these
drugs. However, the binding of BGB659
is unaffected by occupancy of the first
site, and it inhibits monomers and the
second site of dimers with similar potency
(100–300 nM). Our model suggests thatsuch a drug would be effective in treating tumors in which onco-
genic ERK signaling is driven by RAF dimers.
BGB659 Effectively Inhibits ERK Signaling Driven by
Oncogenic BRAF Dimers in Tumor Cells
In A375, expression of mutant NRAS or overexpression of BRAF
V600E caused ERK signaling to become much less sensitive to
RAF monomer selective inhibitors (Figures 5A and S5A). By
contrast, the concentration at which BGB659 inhibits ERK
signaling was affected only marginally by BRAF V600E overex-
pression or mutant NRAS expression (Figure 5B), and it inhibits
ERK signaling in BRAF V600E melanoma SK-MEL-239 and its
resistant counterpart SK-MEL-239 C4 at similar concentrations
(Figure 4B). The effects of these drugs on cell proliferation are
closely correlated with their effects on ERK signaling. The con-
centrations of BGB659 that cause inhibition of the proliferation
of A375, A375-expressing mutant NRAS, or A375-overexpress-
ing BRAF V600E are very similar (Figure S5B). Significantly
higher concentrations of the other tested inhibitors were required
to inhibit the proliferation of melanoma cells with any of the threeptember 14, 2015 ª2015 Elsevier Inc. 377
mechanisms of dimer-dependent resistance (Figures S5B and
S5C). Thus, BGB659 effectively inhibits the growth of melanoma
cells in which acquired resistance to vemurafenib is driven by
truncated or full-length BRAF V600E dimers.
BGB659 also inhibited ERK signaling driven by RAF mutants
that constitutively dimerize. All such mutants are resistant to in-
hibition by 1 mMvemurafenib (Figure 2C; Table 1) but sensitive to
1 mM BGB659 (7 of 10 mutants tested are shown in Figure 5C).
BGB659 also inhibits ERK signaling driven by activated RAF
fusion proteins (KIA1549-BRAF and ESRP1-CRAF) and trunca-
tions (p61 or Cat C) that constitutively dimerize (Figure 5C).
BGB659 effectively inhibits ERK signaling and the proliferation
of JVM-3, a BRAF K601N CLL cell line that is resistant to vemur-
afenib (Figures S5D and S5E). Thus, BGB659 inhibits ERK
signaling driven by both oncogenic RAF monomers and dimers
and inhibits the proliferation of tumor cells harboring these RAF
mutants.
BGB659 Preferentially Inhibits Mutant RAF-Driven ERK
Signaling
An inhibitor of mutant and WT RAF dimers would inhibit ERK in
normal cells and would have a narrow therapeutic index, as
do MEK inhibitors. We compared the effects of BGB659 on
signaling driven by WT dimers and mutant RAF dimers in NIH
3T3 cells in which a variety of RAS or RAF mutants were ex-
pressed in an induciblemanner. The IC50 values for BGB659 inhi-
bition of ERK signaling driven by BRAF V600E monomers or
three differentmutant BRAF constitutive dimers were very similar
and more than an order of magnitude lower than those required
to inhibit signaling in cells in which WT BRAF or NRAS or NRAS
Q61K were overexpressed (Figure S6A). The data suggest that
BGB659 does not inhibit all RAF dimers equally; BRAF mutant
monomers and dimers are more sensitive than RAS-driven WT
RAF dimers. In contrast, after 1 hr of exposure, the MEK inhibitor
trametinib inhibits ERK phosphorylation at similar doses whether
it is driven by WT RAF or mutant BRAF (Figure S6B).
This was also the case in tumor cell lines in which ERK is acti-
vated by different upstream mechanisms (Figure 6A), including
mutant BRAF V600E (A375 melanoma), A375 in which NRAS
Q61K is expressed, mutant NRAS Q61R (SK-MEL-2 mela-
noma), mutant KRAS G12S (A549 lung cancer), and HER2-acti-
vated WT RAS (SKBR3 breast cancer). BGB659 inhibits ERK
signaling at almost identical concentrations in A375 and in
A375 in which mutant NRAS has been overexpressed (IC50
100–300 nM, almost complete inhibition at 1 mM). In contrast,
in the other three cell lines, ERK phosphorylation increased after
exposure to relatively low doses of the drug, with maxima
occurring at 50–100 nM, and declined at higher concentrations.
In SKBR3 and SK-MEL-2, ERK phosphorylation declined 40%
with 1 mM BGB659 and only approached complete inhibition
at 10 mM. In A549 mutant KRAS cells, ERK declined to pretreat-
ment levels at 1 mM drug, and some residual activity remained at
10 mM. Thus, tumor cells with mutant RAF, with or without coex-
istent RAS mutation, are most sensitive to BGB659. In cells in
which ERK is driven by WT RAF (SK-MEL-2, A549, SKBR3),
the effect of the drug varied with concentration in a biphasic
manner, with ERK phosphorylation enhanced at low doses
and inhibited at higher doses. The effects of BGB659 on
tumor cell proliferation correlated with its effects on signaling378 Cancer Cell 28, 370–383, September 14, 2015 ª2015 Elsevier In(Figure S6C). All 15 tumor cell lines with mutant BRAF were
sensitive to the drug (9 with BRAF V600E, 1 with BRAF
V600K, 4 with BRAF mutants that constitutively dimerize, and
1 with p61 BRAF V600E) with IC50 values from 100 to 600 nM.
By contrast, the 10 tumor cell lines with RAS mutation and 14
with WT RAS and RAF were 10- to more than 50-fold less
sensitive than the mutant RAF tumors.
A biphasic dose response is also observed when normal or tu-
mor cells with activated RAS are treated with previously reported
RAF inhibitors (Poulikakos et al., 2010). This phenomenon has
been shown to result from both induction of RAF dimerization
by the drug and its transactivation of RAF dimers (Hatzivassiliou
et al., 2010; Lavoie et al., 2013; Poulikakos et al., 2010). BGB659
inhibits the second site of activated RAF dimers in cells with
mutant NRAS with the same potency as it inhibits BRAF V600E
monomers (Figures S4Ha and S4Hb). We therefore asked
whether its differential effects on mutant and WT RAF dimers
are due to differential induction of dimerization. BGB659 and
other RAF inhibitors caused marked, dose-dependent induction
of BRAF/CRAF heterodimers in HeLa and in two melanoma cell
lines with mutant NRAS, but not in A375 (BRAF V600E) (Fig-
ure 6B). Induction by BGB659, and the RAF monomer inhibitors
LGX 818 and dabrafenib was equivalent and much greater than
that caused by vemurafenib (Figure 6B). Because physiologic
dimerization of RAF is RAS dependent and RAS-GTP levels are
inhibited by feedback in A375, we asked whether induction of
dimerization is RAS dependent. In SKBR3 cells, RAS-GTP levels
and induction of BRAF/CRAF heterodimers by BGB659 were
both inhibited in a dose-dependent fashion by lapatinib and
correlated closely with each other (Figure 6C). These data sug-
gest that induction of dimerization is RAS dependent and does
not occur in cells with activating RAF mutations because their
RAS-GTP levels are low.
In support of this model, we examined the ability of BGB659 to
induce dimerization ofWTRAF in cells with active RAS-GTP (Fig-
ure 6D, lanes 1–6). In SKBR3, BGB659 inducesWT BRAF homo-
dimers and BRAF/CRAF heterodimers (Figure 6D, lane 4 versus
3, lane 6 versus 5). Thus, in cells in which WT RAFs are activated
by active RAS, BGB659 both induces the formation of active RAF
dimers and inhibits their activity.
In contrast, in cells that express activated RAFmutants, RAS is
feedback inhibited, and ERK signaling is RAS independent.
Accordingly, we assessed the effects of BGB659 on RAF dimer-
ization in lapatinib-treated SKBR3 cells engineered to express
different RAF mutants. (Figure 6D, lanes 7–12). In BRAF
mutant-expressing cells, no mutant BRAF or WT CRAF hetero-
dimers are detected. Significant levels of p61 BRAF (Figure 6D,
lanes 7 and 8) and BRAF K601E (Figure 6D, lanes 11 and 12)
homodimers are expressed in cells in which either mutant is ex-
pressed. In cells in which BRAF V600E is expressed, a low level
of mutant homodimers is observed (Figure 6D, lanes 9 and 10).
BGB659 did not induce mutant RAF homo- or heterodimeriza-
tion in any of these cells. Thus, BGB659 induces RAS-dependent
dimerization of WT RAF, but in tumors with mutant RAF, RAS-
GTP levels are too low to support induction of dimerization.
Taken together, these data support the following model.
BGB659 inhibits both sites of RAF dimers and also induces
RAS-dependent RAF dimerization. In cells with adequate levels
of RAS activation, this accounts for the biphasic response toc.
Figure 6. BGB659 Preferentially Inhibits
Signaling Driven by Mutant BRAF Dimers
(A) The indicated cell lines were treated with 0,
10, 30, 100, 300, 1,000, 3,000, and 10,000 nM
BGB659 for 1 hr. Whole-cell lysates were assayed
by western blot with anti-p-ERK antibody. The
p-ERK level of each sample was quantitated by
densitometry and then normalized to the p-ERK
level in untreated cells. The p-ERK response
curves were generated using Prism6.
(B) A375, HeLa, SK-MEL-30, and SK-MEL-2 cells
were treated with the indicated compounds for
1 hr. Endogenous BRAF was immunoprecipitated
with anti-BRAF antibody. The input and isolated
protein complexes were assayed by western blot
as indicated.
(C) SKBR3 cells were pre-treated with lapatinib
at the indicated concentrations for 1 hr, followed
by treatment with 1 mM BGB659 or vehicle. Cell
lysates were then subjected to immunoprecipita-
tion with anti-BRAF antibody or the RAS-GTP
pull-down assay. Binding of CRAF to BRAF and
RAS-GTP levels were determined by western blot.
Expression levels of BRAF and CRAF were deter-
mined using whole-cell lysates.
(D) The indicated RAF proteins were expressed in
SKBR3 cells for 24 hr. Cells were then treated with
either 1 mM lapatinib or the equivalent volume of
DMSO for 1 hr, followed by treatment with 1 mM
BGB659 or DMSO for an additional 1 hr. All cell
lysates were collected and subjected to immuno-
precipitation with an anti-V5 antibody. The isolated
protein complexes and input were analyzed by
western blot.
(E) BRAF-V5, CRAF-V5, BRAF V600E-V5, and
FLAG-tagged NRAS Q61K were transiently ex-
pressed in SKBR3 cells, followed by 1 hr treatment
with 1 mM lapatinib. The cells were then collected
and lysed, and the ectopically expressed RAF
proteins were isolated with anti-V5 beads, fol-
lowed by elution with V5 peptide. The kinase ac-
tivity of isolated RAF kinases was determined by
in vitro kinase assaywith K97RMEK1 as substrate.
The indicated proteins from both input and kinase
assays were assayed by western blot.
See also Figure S6.increasing concentrations of BGB659. In contrast, in cells with
activating RAF mutants, RAS-GTP is low, and the drug inhibits
the activity of RAF dimers without inducing their formation.
Tumors with RAF mutants are thus more sensitive to this drug
than those with mutant RAS or normal cells.
The exceptional case that complicates this model is the BRAF
V600E tumor with acquired resistance due to mutant NRAS.
These tumors are as sensitive to BGB659 as those with BRAF
V600E alone. We asked whether BGB659 affects RAF dimeriza-
tion in cells with co-expression of BRAF V600E and mutant
NRAS (Figure S6D). BRAF homodimers and BRAF/CRAF heter-
odimers are barely detectable in SKBR3 treated with lapatinib.
Co-expression of mutant NRAS with WT RAF significantly in-
creases levels of homo- and heterodimers and BGB659 further
enhances expression of these dimers (Figure S6D, lanes 2–4).
When BRAF V600E and WT CRAF are overexpressed in
SKBR3, BRAF V600E homodimers and heterodimers were
barely detectable. These dimers were markedly enhancedCanwhen mutant NRAS was co-expressed and further enhanced
by BGB659 (Figure S6D, lanes 6–8). Thus, the drug can induce
BRAF V600E dimerization in tumors that co-express mutant
RAS. However, in this case, induction of BRAF V600E dimeriza-
tion is not associated with a significant induction of RAF kinase
activity (Figure 6E). Co-expression of mutant NRAS induces
BRAF V600E dimerization (Figure S6D); it has almost no effect
on elevated RAF kinase activity (Figure 6E, lanes 8–10). This is
consistent with our data that RAF inhibitors do not paradoxically
activate p-ERK in such tumors. By contrast, co-expression of
WT BRAF or CRAF with mutant NRAS is associated with
increased RAF kinase activity (Figure 6E, lanes 2–6). Thus,
BGB659 effectively inhibits ERK signaling in tumors that co-
express BRAF V600E and mutant RAS because in these
cells, it induces BRAF V600E dimerization, but not kinase activa-
tion. BGB659 works less well in cells with active RAS and
WT RAF, because it increases RAF kinase activity by inducing
dimerization.cer Cell 28, 370–383, September 14, 2015 ª2015 Elsevier Inc. 379
Figure 7. BGB659 Inhibits the In Vivo
Growth of BRAF V600E Tumors with
Acquired Resistance to Vemurafenib
(A and B) SK-MEL-239 parental or C4 clone (p61
V600E) cells were injected subcutaneously into the
opposite flanks of nude mice (1.5 3 107 cells per
injection). After 10 days, all 12 tumors from each
group were 100–150 mm3 in size, and the indi-
cated drug treatments were started. The graph
shows the size of each tumor after 32 days of daily
treatment (A) (n = 12, error bars indicate mean ±
SEM, p valueswere calculated using the unpaired t
test). Protein extracts from 4 randomly selected
tumors from each group were analyzed by western
blot using the antibodies indicated (B).BGB659 Inhibits the In Vivo Growth of Tumors Driven by
Mutant RAF Monomers or Dimers
Figures 6 and S6 suggest that BGB659 will inhibit ERK
signaling in tumors driven by activating RAF mutants and fusion
proteins more effectively than in normal cells and could there-
fore be useful clinically. We tested whether BGB659 could
inhibit the in vivo growth of SK-MEL-239 C4, cells in which ac-
quired resistance to vemurafenib is mediated by the p61 BRAF
V600E dimer. This model and the vemurafenib-sensitive
parental SK-MEL-239 cell line were grown as subcutaneous
murine xenografts. BGB659 (100 mg/kg) given daily was unas-
sociated with weight loss or other obvious toxicity. Mice car-
rying 100 mm3 tumors were treated daily for 32 days with
vehicle, 75 mg/kg vemurafenib, or 100 mg/kg BGB659 and
then analyzed. Vemurafenib and BGB659 both effectively in-
hibited the growth of SK-MEL-239 tumors, but only the latter
had activity against SK-MEL-239 C4 tumors (Figure 7A).
Consistently, vemurafenib and BGB659 both potently inhibited
ERK signaling in SK-MEL-239 tumors, but only BGB659 in-
hibited ERK signaling in SK-MEL-239 C4 tumors (Figure 7B).
These results support the possibility that drugs of this class
could be effective in tumors driven by either mutant RAF mono-
mers or dimers, including those that mediate acquired resis-
tance to current RAF inhibitors.
DISCUSSION
Almost 200 BRAF mutants and many RAF translocations have
been identified in human cancer, and many of those have
increased catalytic activity (Wan et al., 2004; Palanisamy et al.,380 Cancer Cell 28, 370–383, September 14, 2015 ª2015 Elsevier Inc.2010). Our work divides the activating
mutants into two functional classes on
the basis of the mechanism whereby
they achieve RAS independence. The
dimerization of BRAF V600 mutants re-
mains RAS dependent, but they also
signal as RAS-independent monomers
in tumor cells in which RAS is inhibited
by feedback. All of the other tested RAF
mutants and fusion proteins signal as
RAS-independent constitutive dimers.
These data support the idea that
insensitivity to physiologic feedback is acommon property of oncoproteins that is required for their
hyperactivation of signaling output.
None of the RAFmutants that signal as constitutive dimers are
sensitive to the previously reported RAF inhibitor vemurafenib.
This drug preferentially inhibits active RAF monomers, which
comprise all four of the BRAF V600 mutant alleles found in pa-
tients. These mutants are capable of signaling as monomers or
RAS-dependent dimers; the feedback inhibition of RAS by
ERK causes BRAF V600 mutants to exist as drug-sensitive
monomers in these tumors. Moreover, the three most common
causes of acquired resistance of BRAF V600E melanomas to
RAF inhibitors—NRAS mutation, splicing of BRAF V600E that
produces a truncated BRAF kinase, and BRAF V600E overex-
pression due to gene amplification—all cause resistance by
causing dimerization of BRAF V600E.
The mechanisms underlying the characteristic effects of RAF
inhibitors, inhibition of BRAF V600E monomers, resistance of
RAF dimers, and activation of ERK signaling in cells with active
RAS and WT RAF remain controversial. The designation of
these drugs as selective inhibitors of BRAF persists in the med-
ical literature despite evidence to the contrary. They have been
shown to inhibit the kinase activities of all three RAF family
members in vitro and to activate ERK signaling in BRAF KO cells
with active RAS (Poulikakos et al., 2010). We show here that
BRAF mutants that constitutively dimerize are resistant to these
drugs, as are V600E dimers in cells with coexistent NRAS mu-
tation or overexpressing V600E. These drugs would be better
described as inhibitors of BRAF monomers. However, why
these drugs are poor inhibitors of dimers is poorly understood.
Binding of RAF inhibitors to one protomer in the WT CRAF dimer
causes the allosteric transactivation of the unbound protomer.
Most inhibitors also cause RAF to dimerize. Both of these ef-
fects play a role in transactivation but cannot, by themselves,
explain paradoxical activation of WT dimers or the insensitivity
of mutant dimers, because, even if binding of the inhibitor to
one protomer causes the other to adopt an active conformation,
the drug ought to bind to the second site in the dimer with
similar potency.
The obvious hypothesis is that binding of the drug to one site in
the dimer causes an allosteric effect that reduces its affinity for
the second site. We now provide evidence that this is the case.
In isogenic models, the concentrations of RAF inhibitor required
to inhibit the monomer were much lower than those required to
inhibit the dimer. We take these findings as reflecting the differ-
ence in concentration required to inhibit the first and second
sites of the dimer and therefore demonstrating that negative co-
operativity is induced on occupancy of the first site by the drug.
This ideawas supported by experiments in which the off-rate of a
RAF inhibitor from the first and second sites of an active WT
dimer were measured in cells, and the latter was found to be
considerably faster than the former. This system was used to
measure the concentrations at which several RAF inhibitors
inhibit the second site when the first was occupied by the low
off-rate drug. In all cases, the concentration at which the stan-
dard RAF inhibitors block signaling driven by the second site is
considerably higher than the concentration required for them
to inhibit BRAF V600E monomers. Taken together, these data
suggest that significantly higher concentrations of RAF inhibitors
are required to inhibit dimers than monomers because occu-
pancy of the first site in the dimer by the drug reduces its affinity
for the second site.
Our data suggest that an inhibitor of RAF dimers could be
useful for the treatment of many types of ERK-dependent tu-
mors. We identified BGB659 that inhibits BRAF dimers at about
the same concentration as monomers. Moreover, binding of
BGB659 to RAF dimers is unaffected by induction of negative
cooperativity by drug occupancy of the first site. As predicted,
BGB659 inhibits ERK signaling driven by both active monomers
and constitutively activated dimers. It also inhibits ERK
signaling in models in which acquired resistance to standard
RAF inhibitors is mediated by mutant BRAF dimers. However,
because it also induces the formation of activated WT RAF di-
mers in cells with active RAS, it is a much less potent inhibitor
of ERK signaling in normal cells and in tumors with RAS
mutation.
This work has several important clinical implications. First, it
suggests that current RAF inhibitors will be effective in tumors
driven by BRAF V600 mutants and not in those driven by any
of the other, constitutively dimerizing, BRAF mutants or translo-
cations. This must be a tentative conclusion, because we do not
understand the structural basis whereby all of these mutants
(including K601E) form constitutive RAS-independent dimers,
and only BRAF V600 mutants can signal as either dimers or
monomers. Crystal structures have not shed light on this ques-
tion, perhaps because they all lack the amino-terminal portion
of RAF proteins that is critical in regulating dimerization. We
are therefore engaged in characterizing the RAS and dimeriza-
tion dependence of all mutant RAF alleles found in tumors and
determining their sensitivity to inhibitors.CanSecond, we describe herein an algorithm for assessing the
mechanism of action and drug sensitivity of uncharacterized or
newly identified mutations and translocations.
Third, BGB659 inhibits ERK signaling driven by mutant RAF
monomers and dimers at doses at which it does not inhibit
signaling in normal cells. These data suggest that this type of
drug will have a wide therapeutic index and could be effective
in tumors in which current RAF inhibitors are ineffective: tumors
driven by non-V600E BRAF mutants, activating RAF dimers
encoded by gene translocations, and BRAF V600E tumors in
which acquired resistance to RAF inhibitor is due to dimerization.
It is also possible that such a drug will be superior to currently
available RAF inhibitors as an initial treatment to the tumors
driven by BRAF V600E, because they will not be subject to
many of the most common mechanisms of acquired resistance
to those drugs.With the widespread sequencing of human tumor
tissue, many such fusion and non-BRAF V600-activating




BGB283 and BGB659 were obtained from BeiGene. Vemurafenib, PLX7904,
and PLX8394 were obtained from Plexxikon. Lapatinib, trametinib, and dabra-
fenib were obtained from GlaxoSmithKline. LGX818 was obtained from from
Novartis. LY3009120 was purchased from Active Biochem; doxycycline
fromSigmaAldrich; puromycin and hygromycin stock solution from Invitrogen;
and other drugs from Selleckchem. Drugs were dissolved in DMSO to yield
10 mM stock and stored at 20C.
Cell Culture
All cell lines were obtained from either the Memorial Sloan-Kettering Cancer
Center (MSKCC) cell collection or the American Type Culture Collection,
except the conditional RAS KO cell line, which was provided by Mariano Bar-
bacid. 22RV1, H1395, OCI/AML3, U266, JVM-3, and SIG-M5 were cultured in
RPMI + 10% fetal bovine serum (FBS). Keratinocytes were maintained in the
Defined K-SFMmedium fromGIBCO. All other cell lines were grown in Dulbec-
co’s modified Eagle’s medium with glutamine, antibiotics, and 10% FBS. The
inducible expression cells were maintained in the medium with 50 mg/ml hy-
gromycin and 0.2 mg/ml puromycin.
Antibodies
Western blot, immunoprecipitation, and in vitro kinase assays were
performed as described (Poulikakos et al., 2011). The following anti-
bodies were used: anti-p217/p221-MEK1/2 (p-MEK1/2), anti-p202/p204-
ERK1/2 (p-ERK1/2), anti-MEK1/2, anti-ERK1/2 from Cell Signaling,
anti-V5 from Invitrogen, anti-BRAF from Santa Cruz Biotechnology, anti-
FLAG from Sigma, anti-CRAF from BD Transduction Laboratories, and
anti-CRAF-S338 from Millipore. For immunoprecipitations of tagged
proteins, the following reagents were used: anti-V5 agarose affinity gel
(Invitrogen), anti-Flag M2 affinity gel (Sigma), and protein G agarose gel
(Invitrogen).
Plasmids
The pcDNA3-BRAF-V5/FLAG/myc, pcDNA3-CRAF-V5/FLAG/myc, pcDNA3-
catC-FLAG, and pcDNA3-p61/p61 R509H were constructed as previously
described (Poulikakos et al., 2010, 2011). The ESRP1-RAF1 and
KIAA1549-BRAF fusion genes were sub-cloned into pcDNA3 with FLAG or
V5 tag. Plasmids for retroviral-based inducible expression system were
provided by Scott Lowe’s lab at MSKCC. The BRAF and NRAS genes
were sub-cloned into TTIGFP-MLUEX vector harboring tet-regulated pro-
moter. Mutations were introduced by using the site-directed Mutagenesis
Kit (Stratagene).cer Cell 28, 370–383, September 14, 2015 ª2015 Elsevier Inc. 381
Animal Model Studies
Nu/nu athymic mice were obtained from Harlan Laboratories and maintained
in compliance with Institutional Animal Care and Use Committee (IACUC)
guidelines. Subcutaneous xenografts and tumor measurements were per-
formed as described. All studies were performed in compliance with institu-
tional guidelines under an IACUC-approved protocol.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.ccell.2015.08.001.
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